Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.
Blood Adv. 2023 Aug 22;7(16):4448-4461. doi: 10.1182/bloodadvances.2022009596.
Blood Adv. 2023.
PMID: 37276451
Free PMC article.
The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions.
Rusconi S, Santoro MM, Capetti AF, Gianotti N, Zazzi M.
Rusconi S, et al.
Int J Antimicrob Agents. 2022 Sep;60(3):106627. doi: 10.1016/j.ijantimicag.2022.106627. Epub 2022 Jun 24.
Int J Antimicrob Agents. 2022.
PMID: 35760225
Review.
The approval of the long-acting, once-monthly or bimonthly injectable combination of the second-generation strand transfer integrase inhibitor (InSTI), cabotegravir (CAB) together with the non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (RPV) represents the mo …
The approval of the long-acting, once-monthly or bimonthly injectable combination of the second-generation strand transfer integrase inhibit …
Item in Clipboard
Cite
Cite